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Background: We sought to examine differences in response rates to quality of life (QoL) surveys in patients treated
surgically for renal cell carcinoma (RCC) and prostate cancer (PCa) and to analyze factors associated with non-response
of the surveys.
Methods: Patients who underwent surgery for RCC or PCa between 2006 and 2012 were offered enrollment in
respective prospective cancer registries that included baseline and annual QoL assessments. We identified 201
RCC patients and 616 PCa patients who completed a baseline QoL survey and were mailed annual QoL surveys
[RCC: SF-36, FACT–G (73 questions), PCa: EPIC, IIEF, Max-PC (80 questions)]. We compared patient characteristics
between responders and non-responders using a Wilcoxon rank-sum test for continuous variables and a Fisher’s
Exact test for categorical variables.
Results: The overall response rates for the PCa and RCC groups were 63 and 48 % (p < 0.001), respectively. This
difference in response rates remained when we limited analysis to only those with early stage disease (pT2 for
PCa and pT1 RCC, 62 % vs. 52 %; p = 0.03). PCa characteristics associated with response included older age (64.1
vs 62.6 years, p = 0.032) and robotic versus open surgery (56 % vs 44 %; p = 0.009). There were no characteristics
that were associated with response in RCC patients.
Conclusions: Surgically treated PCa patients have higher QoL mail-based survey response rates compared to patients
treated surgically for RCC. This difference holds true for clinically localized cancers as well.
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Five-year survival for surgically treated pT1 RCC is over
90 % [1, 2], and 10 year cancer specific survival for sur-
gically treated intermediate risk PCa is over 95 % [3]. A
downstream effect of these longer survival times has
been a parallel increase in the desire to evaluate factors
that affect post-surgical quality of life (QoL). Survey-
based instruments to measure specific metrics related to
patient QoL (eg, depression, cancer-specific anxiety, etc.)* Correspondence: thiel.david@mayo.edu
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ments have been shown to improve physician-patient
communication and provide increased individualization
of treatment and self-assessment of physician surgical
outcomes [4, 5]. Despite the benefit to both research and
clinical practice, only about 20 % of urologists report
utilizing QoL assessments as part of their management
of PCa patients, and patient response rates to these QoL
assessments have been shown to vary considerably [6].
This underscores the need to improve our overall under-
standing of the response rates to QoL assessments in thesecle distributed under the terms of the Creative Commons Attribution License
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predict patient response and non-response.
We harnessed resources at our institution to evaluate
response to postoperative QoL surveys in PCa and RCC.
We hypothesized that there is a difference in response
rates to postoperative QoL surveys between PCa and
RCC patients. To test our hypotheses, we utilized data
collected as part of two cancer registry efforts at our in-
stitution (one for PCa and one for RCC), which include
baseline QoL assessment followed by annual evaluations
of QoL. We report herein our analysis of the response
rates between the two patient populations as well as our
assessment of factors associated with response rates for
each group, respectively.
Methods
RCC Patients: Patients who underwent surgery for RCC
at our institution between 2006 and 2012 were offered
Mayo Clinic Institutional Review Board-approved en-
rollment in a prospective registry that included baseline
and annual QoL assessment. Patients either underwent
nephrectomy or partial nephrectomy that was completed
laparoscopically or with an open incision. Patients gave
written consent and completed QoL surveys at baseline
and were mailed follow-up QoL surveys at postoperative
year one and two. The QoL surveys mailed were the SF-
36 and the FACT-G (Functional Assessment of Cancer
Therapy-General). There were a total of 73 questions in
the two surveys.
The SF-36 uses 36 questions to assess eight domains
of functional health and well-being. It is non-specific to
age, disease, and treatment, which is useful in both general
and specific populations. All 36 questions on the SF-36
are scored on a scale from 0 to 100, with 100 as the high-
est level of functioning. Collective scores are calculated as
a percentage of the total points possible. The scores from
those questions that address each specific domain of func-
tional health status are averaged together for a final score
with each of the eight domains assessed [7].
The FACT-G is a 33-item questionnaire that measures
four QoL domains; physical, social, emotional, and func-
tional well-being, with nine additional questions dedicated
to establishing QoL associated with RCC [8]. The FACT-G
is scored by adding the individual scores (range 0 to 108),
with higher scores indicating better QoL.
PCa patients: Patients who opted to enroll in the Insti-
tutional Review Board-approved PCa registry completed
baseline QoL surveys prior to surgical therapy and were
mailed follow-up questionnaires 6 months following
surgery and then annually thereafter. PCa was treated
surgically at our institution with radical retropubic
prostatectomy (RRP) or robotic prostatectomy (RARP).
The PCa surveys used were the EPIC, IIEF, and Max-PC
surveys totalling 80 questions.The EPIC (expanded prostate cancer index composite)
is a prostate-specific instrument utilized to assess health
related QoL with regard to function and bother. The in-
strument assesses urinary, bowel, sexual, and hormonal
domains. Three scores are provided for each of the do-
mains to provide a function score, a bother score, and a
total score [9]. Higher scores reflect better function.
The IIEF (International Index for Erectile Function) is
a brief, reliable, self-administered survey of erectile func-
tion that is cross-culturally valid and psychometrically
sound. The IIEF addresses the relevant domains of male
sexual function (erectile function, orgasmic function, sex-
ual desire, intercourse satisfaction, and overall satisfaction)
and has been linguistically validated in 10 languages.
The IIEF demonstrates the sensitivity and specificity for
detecting treatment-related changes in patients with
erectile dysfunction [10].
The Max-PC survey (Memorial Anxiety Scale for Pros-
tate Cancer) was developed to facilitate the identification
and assessment of men with prostate cancer-related anx-
iety. This scale consists of three subscales that measure
general prostate cancer anxiety, anxiety related to prostate
specific antigen (PSA) levels in particular, and fear of re-
currence [11]. It should be noted that patients who did
not respond to the questionnaires were not contacted
again until the following year. Patients were not contacted
by phone or e-mail or sent another questionnaire if there
was no response that year.
Study Analysis: We compared patient characteristics
between responders (those who returned at least a one- or
two-year follow-up survey) and non-responders (those
who did not return any follow-up surveys). For the RCC
registry, only RCC patients were included. Those with
alternative pathology (such as oncocytoma, papillary
adenoma, etc.) were excluded. All patients who under-
went surgery for PCa were included. The PCa patients
do receive a 6 month postoperative survey which was
not included in the analysis. The analysis included patients
treated surgically between 2006 and 2012 to allow for ana-
lysis of 1 year response rates.
Statistical analysis: Continuous variables were presented
as median, minimum, and maximum values. Categorical
data were presented as counts and percentages. Compari-
sons of patient characteristics between responders (who
completed at least a one- or two-year annual follow-up)
and non-responders were performed using a Wilcoxon
rank-sum test for continuous variables and a Fisher’s Exact
test for categorical variables. The cumulative mortality
rates were estimated using the Kaplan-Meier method and
comparison between mortality of responders versus non-
responders was evaluated using Cox Proportional Hazards
models. All statistical tests were two-sided, with threshold
of significance set at a = 0.05 and performed using SAS
Version 9.2 (SAS Institute Inc., Cary, NC).
Table 2 Association of patient and surgical characteristics in







Age at surgery 62.6 (29.9, 76.8) 64.1 (42.9, 78.4) 0.032
Surgery type
RRP 83 (36 %) 171 (44 %) 0.009
RARP 147 (64 %) 215 (56 %)
T stage 0.51
pT1 0 (0 %) 3 (1 %)
pT2 200 (87 %) 328 (85 %)
pT3, pT4 30 (13 %) 54 (14 %)
Pathological Gleason score 0.71
4-6 86 (37 %) 139 (36 %)
7 123 (53 %) 211 (55 %)
8-10 21 (9 %) 36 (9 %)
aMedian [Minimum, Maximum] is given for continuous measures, and N (%)
for categorical measures
bP-values for age at surgery and Gleason score are based on Wilcoxon Rank
Sum test. P-values given for T-stage are based on Fisher’s Exact test
PCa = prostate cancer
QoL = quality of life
RRP = Radical Retropubic Prostatectomy
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We identified 201 patients in the RCC registry and 616
patients in the PCa registry who were surgically treated
between 2006 and 2012 and were asked to fill out a
baseline QoL survey and a follow-up QoL survey at
1 year following surgery and annually thereafter. The
overall response rates for the PCa and RCC groups
were 63 and 48 % (p < 0.001), respectively.
Table 1 outlines the patient and surgical characteristics
in the 201 RCC patients stratified by non-response ver-
sus response rates. Surgery type (partial nephrectomy
or radical nephrectomy), surgical approach (laparoscopic
versus open surgery), T stage, or nuclear grade were not
significantly associated with increased response rates.
Table 2 summarizes the 616 PCa patients in the PCa
registry organized by response status and their associ-
ation with the type of surgery performed, T stage, and
Gleason score. Unlike RCC patients, there was an associ-
ation with response rates with regard to age at surgery and
surgery type (RRP versus RARP). Much like the RCC
group, there was no association with response rates and
prognostic variables, such as T stage or Gleason score.
Table 3 is a summary of the response rates of stage
pT1 RCC patients compared to stage pT2 PCa patients.Table 1 Association of patient and surgical characteristics in
n = 201 RCC patients non-response versus response to QoL
collected at one- or two-year follow-up
Variablea Non-responder (n = 105) Responder (n = 96) P-valueb
Age at surgery 65.2 (24.0, 87.5) 67.3 (35.3, 92.1) 0.48
Sex, male 75 (71 %) 62 (65 %) 0.36
Surgery type
Partial 37 (35 %) 44 (46 %) 0.15
Radical 68 (65 %) 52 (54 %)
Surgery type 0.88
Open 33 (31 %) 29 (30 %)
LAP 72 (69 %) 67 (70 %)
T stage 0.14
pT1 69 (68 %) 74 (79 %)
pT2 9 (9 %) 8 (9 %)
pT3, pT4 24 (24 %) 12 (13 %)
Nuclear grade 0.098
1 4 (4 %) 9 (10 %)
2 62 (60 %) 59 (63 %)
3-4 37 (36 %) 26 (28 %)
aMedian [Minimum, Maximum] is given for continuous measures, and N (%)
for categorical measures
bP-values for age at surgery and nuclear grade are based on Wilcoxon Rank
Sum test. P-values given for Sex, Radical/partial surgical type, Open/LAP surgical
type, and T-stage are based on Fisher’s Exact test
RCC = renal cell carcinomaQoL = quality of life
LAP = Laparoscopic
RARP = Robot-Assisted Radical ProstatectomyDespite similar prognoses, the pT2 stage PCa patients
are more likely to respond than pT1 RCC patients (62 %
vs. 52 % p = 0.027).
Figure 1a and b demonstrate the survey response rates
in relation to cancer specific mortality. It is obvious from
both graphs that RCC patients were more likely to die
(26 out of 201 RCC deaths) than PCa patients (7 out of
616 PCa deaths). Figure 1a demonstrates that RCC mor-
tality was correlated with non-responder status, and this
difference remains even when non-responders who died
within the first year after surgery are excluded. Figure 1b
illustrates that PCa mortality did not affect questionnaire
response rates.
Discussion
QoL instruments have been shown to improve physician-
patient communication, individualization of treatment, and
physician self-assessment of surgical outcomes [4, 5].
Despite the advantages of QoL instruments, their use by
urologists in addition to overall response rates by patientsTable 3 Questionnaire return rates of pT1 RCC patients and pT2
PCa patients
Variable Non-responder (n = 269) Responder (n = 402) P-value
RCC pT1 only 69 (48 %) 74 (52 %) 0.027
PCa pT2 only 200 (38 %) 328 (62 %)
RCC = renal cell carcinoma
PCa = prostate cancer
Fig. 1 Association of questionnaire return rates with cancer specific mortality: Figure 1a demonstrates that 201 RCC patient questionnaire
response rates are associated with RCC mortality. Figure 1b demonstrates that cumulative PCa mortality following surgery is not associated
with response rates
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instruments utilized for PCa is that these surveys are diffi-
cult to seamlessly integrate into practice and often take
too much time to score and analyze [6]. Some have argued
that these surveys may be too complex for the common
patient; however, a recent analysis of the readability of
QoL instruments utilized in urology practice for the most
burdensome diseases notes that the reading level for these
surveys is appropriate for the reading ability of most
American adults [4].
A previous analysis of RCC patients at our institution
revealed that RCC patients do not necessarily express high
levels of concern following surgical treatment secondarily
to feeling “cured” [8]. The study noted patients to have
mood and anxiety changes early on following surgery, but
those changes dissipated with longer-term follow-up. Our
QoL instruments are mailed 1 year following surgery, and
this time interval certainly allows patients time to recover
from surgery and undergo follow-up imaging, possibly
re-enforcing the feeling of being “cured.” This may have
contributed to the lower mail return rate for the QoL in-
struments in RCC patients. However, a man who has had
a prostatectomy for clinically localized PCa has only a
chance of approximately 2-3 % of dying from that disease
within a decade, and this would certainly reinforce the
feeling of being “cured” [3]. Figure 1 demonstrates that
RCC patients are much more likely to die over this short
follow-up period than their PCa counterparts. However,
when patients with pT1 RCC (who have over 90 % 5 year
survival) were compared to pT2 PCa patients in this study,
a disparate number of questionnaire responses in favor of
the PCa group remained.
One possible reason for the disparity in survey re-
sponse rates seen in our study between PCa and RCCpatients may relate to the treatment decision-making
process. RCC patients have few options other than sur-
gery or ablation for their renal mass, which is especially
true in clinically localized pT1 tumors. In contrast, patients
with clinically localized PCa must decide between a
multitude of treatment options such as active surveillance,
cryoablation, ultrasound ablation, various radiotherapies,
and surgery. The many choices make information gathering
paramount and likely underlines the QoL return as a strong
focus of PCa follow-up.
A Google search for “Prostate Cancer Treatment Op-
tions” currently results in 37 million hits compared to
approximately 27 million hits for “Kidney Cancer Treat-
ment Options.” Media exposure and the high prevalence
of PCa in aging males may make PCa more socially ac-
ceptable and easier to discuss in open forums compared
to other cancers. The media exposure and the associated
competitive marketing may also be setting men with
PCa up for unreal expectations regarding post-therapy
outcomes. One analysis demonstrated that men who
had a RARP for PCa were more likely to experience
treatment regret and dissatisfaction [12]. It is unknown
what effect this may have on questionnaire return rates,
but patients who had RARP were more likely to respond
to QoL surveys than RRP patients.
Another possible reason for the disparity in return rates
between RCC patients and PCa patients are the overall op-
erative experiences of the two diseases. There may be a
difference in postoperative expectations and QoL per-
ception among patients with RCC and PCa. A diagnosis
of RCC or PCa may each carry with it the fear of death.
However, patients treated for PCa often carry the additional
fear of recovering urinary continence and sexual potency
[13]. This fact alone may explain why PCa patients are very
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take to return to baseline QoL parameters. It also must be
considered that full recovery of continence and potency
following PCa surgery may take up to 24 months [14].
One concern with QoL questionnaire response rates is
the length of the surveys. Patients may be unwilling to
take the time to fill out lengthy surveys. The PCa and
RCC question totals were similar in our registries (80
versus 73 questions) so we do not anticipate that sur-
vey length played a role in response rates between RCC
and PCa.
One-year QoL response rates in patients surgically
treated for PCa are reported as high as 93 % [15]. Two
European studies analyzing the QoL of patients follow-
ing surgery for RCC noted response rates of 71 and
72 % over a 6 month period, with one of the studies util-
izing the same SF-36 survey used in this study [15, 16].
As evidenced by the studies above, the QoL response
rates in both registries in our study are suboptimal. Our
institution is looking into methods that may improve
our overall QoL response rates. A 2012 examination of
QoL outcomes following renal surgery gave patients the
option of internet or paper-based follow-up [17]. Pa-
tients who did not respond were contacted by phone or
e-mail up to three times. This led to a QoL response rate
of 85 % over a 24 week period. Contacting patients via
e-mail or phone calls may improve response rates, but it
may also lead to inequality of data collection or recall
bias, which may influence the results achieved. With
regard to PCa, it has been noted that there is a wide
gap between patient reported QoL outcomes and those
assessed by physicians [18]. Therefore, we believe it is
important to continue our current practice of mailing
the surveys to the patients. One strategy to explore is
direct emphasis to the patient by the surgeon on the
importance of QoL survey return. Another option be-
ing explored is to deliver QoL survey material during
follow-up visits. However, much of our patient population
travels a great distance for surgery and receives their can-
cer follow-up locally, which may make this second option
implausible.
Our RCC and PCa registries utilize mail surveys to
collect QoL data and one strength of our study is that
both surveys are collected in the same manner, which al-
lows us to directly compare QoL return rates. However,
this is a single-institution, retrospective study that has a
few limitations as a result. One limitation of the study is
the small sample size in both registries. This small sample
size decreases our power to detect potentially meaningful
differences between the PCa and RCC groups. Another
limitation is that it involves a sample drawn from a tertiary
care center, and the information may not be generalizable
to the population as a whole. The respondents in the study
were predominantly men, and it is unclear what effect thishas on questionnaire response rates. In addition, patient-
specific factors such as race and socioeconomic status
were not included for analysis and may affect patient re-
sponse rates. Another factor that may affect response rates
that is not recorded is whether or not patients with recur-
rent cancer are undergoing adjuvant or salvage therapy.
Also, it should be noted that the surveys for each popula-
tion were different, with differing numbers of questions,
which may have been another factor possibly impacting
survey response rates.
Conclusions
At our institution, patients who are surgically treated for
PCa are more likely to participate in QoL mail surveys
than surgically treated RCC patients. QoL response rates
for both groups of patients remains suboptimal, and other
strategies may be necessary to achieve maximum assess-
ment of postoperative QoL for RCC and PCa patients.
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